MCM
TGTX icon

MAI Capital Management’s TG Therapeutics TGTX Stock Holding History

MAI Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$439K Buy
7,992
+1,705
+27% +$69.8K ﹤0.01% 1368
2026
Q1 		$209K Buy
6,287
+948
+18% +$28.3K ﹤0.01% 1439
2025
Q4 		$159K Sell
5,339
-77
-1% -$2.52K ﹤0.01% 1405
2025
Q3 		$196K Sell
5,416
-52
-1% -$1.71K ﹤0.01% 1270
2025
Q2 		$197K Sell
5,468
-1,775
-25% -$66.1K ﹤0.01% 1183
2025
Q1 		$286K Buy
7,243
+5,243
+262% +$176K ﹤0.01% 996
2024
Q4 		$60.2K Buy
+2,000
New +$57.4K ﹤0.01% 1671

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

MAI Capital Management's TGTX Position: Q2 2026 in Review

MAI Capital Management increased its TG Therapeutics (TGTX) stake by 27% in Q2 2026, buying an estimated $69.8K and bringing the position to 7,992 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

MAI Capital Management first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • MAI Capital Management held 7,992 shares of TG Therapeutics worth $439K as of Q2 2026.
  • MAI Capital Management bought 1,705 TG Therapeutics shares in Q2 2026, an estimated $69.8K.
  • TG Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1368 holding.
  • MAI Capital Management first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.